ROCKET PHARMACEUTICALS, INC.

During the nine months ended September 30, 2025, operating activities used $155.2 million of cash and cash equivalents, primarily resulting from our net loss of $180.6 million offset by net non-cash charges of $33.9 million, including non-cash stock-based compensation expense of $30.9 million, depreciation and amortization expense of $8.8 million, partially offset by accretion of discount on investments of $5.9 million. Changes in our operating assets and liabilities for the nine months ended September 30, 2025, included a decrease in accounts payable and accrued expenses of $9.4 million and an increase in our prepaid expenses of $0.9 million.

During the nine months ended September 30, 2024, operating activities used $162.8 million of cash and cash equivalents, primarily resulting from our net loss of $198.4 million offset by net non-cash charges of $31.1 million, including non-cash stock-based compensation expense of $32.8 million, depreciation and amortization expense of $7.0 million, partially offset by accretion of discount on investments of $6.8 million and reduction in fair value of warrant liabilities of $1.9 million. Changes in our operating assets and liabilities for the nine months ended September 30, 2024, included an increase in accounts payable and accrued expenses of $5.3 million and an increase in our prepaid expenses of $1.0 million.